Vaccine

Defence Therapeutics Collaboration Agreement with Orano to Develop the Next Generation of Targeted Radio-Immunotherapy for Cancer Advances

Vancouver, British Columbia--(Newsfile Corp. - August 13, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or…

1 year ago

Applied DNA Announces Third Quarter Fiscal Year 2024 Financial Results

- Conference Call/Webcast Scheduled for Today at 4:30 PM ET - STONY BROOK, NY / ACCESSWIRE / August 8, 2024…

1 year ago

NanoViricides Provides an Update on Its Clinical Program and Strategy – NV-387 Could be As Revolutionary as Antibiotics

SHELTON, CT / ACCESSWIRE / August 8, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader…

2 years ago

Adlai Nortye Reports Unaudited First Half 2024 Financial Results and Highlights Recent Operational Progress

Company Announces Appointment of Roger Sawhney, M.D. as a New Member of the Board of DirectorsSINGAPORE and NORTH BRUNSWICK, N.J.…

2 years ago

Evaxion to Present One-Year Clinical Efficacy Data from its Phase 2 Study on Lead Cancer Vaccine Candidate, EVX-01, at the ESMO Congress 2024 in September

COPENHAGEN, Denmark, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in…

2 years ago

Alpha Pro Tech, Ltd. Announces Second Quarter 2024 Financial Results

Net income for the quarter ended June 30, 2024 was $1.6 million or $0.15 per diluted share, compared to net…

2 years ago

PDS Biotech to Announce Second Quarter Financial Results on August 13, 2024

PRINCETON, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage…

2 years ago

Flagship Pioneering Announces Appointment of Raj Panjabi as Senior Partner

Former White House Top Health Security Official to Lead Flagship's Preemptive Health and Medicine Initiative CAMBRIDGE, Mass., Aug. 6, 2024…

2 years ago

TFF Pharmaceuticals Provides Continued Positive Outcomes from Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant Rejection

Patient enrollment has accelerated, now with 13 patients enrolled in trial TFF TAC at ~20% of the oral tacrolimus dose…

2 years ago

Emergent BioSolutions Expands NARCAN® Nasal Spray Distribution Capabilities to Enhance Customer Delivery Experience Across the Country

Customer-focused approach and continued investments in NARCAN® Nasal Spray supply-readiness efforts help ensure opioid emergency preparedness GAITHERSBURG, Md., Aug. 06,…

2 years ago